Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. With the ARVO 2021 Annual Meeting being moved to a virtual format, video-recorded presentations are scheduled to become available online at ARVOLearn on May 1, 2021.
"We are pleased to be presenting data on our pre-clinical and clinical programs at this year’s annual meeting, including updated data on two of our key programs, OTX-TKI for the treatment of wet AMD and OTX-TIC for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension," commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix.
Online presentations are expected to be hosted in the Media library catalog within ARVOLearn.
https://finance.yahoo.com/news/ocular-therapeutix-present-pre-clinical-120000910.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.